| Patent Number |
Title Of Patent |
Date Issued |
| 5862999 |
Method of grinding pharmaceutical substances |
January 26, 1999 |
| A method of preparing submicron particles of a therapeutic or diagnostic agent which comprises grinding the agent in the presence of grinding media having a mean particle size of less than about 75 microns. In a preferred embodiment, the grinding media is a polymeric resin. The method pr |
| 5834025 |
Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiologica |
November 10, 1998 |
| Disclosed are methods of intravenous administration of nanoparticulate drug formulations to a mammal to avoid adverse hemodynamic effects: by reducing the rate and concentration of the nanoparticles in the formulations; or by pre-treating the subject with histamine; or by pretreating the |
| 5747001 |
Aerosols containing beclomethazone nanoparticle dispersions |
May 5, 1998 |
| There is disclosed an aerosol comprising droplets of an aqueous dispersion of nanoparticles, said nanoparticles comprising insoluble beclomethazone particles having a surface modifier on the surface thereof. There is also disclosed a method for making the aerosol and methods for treatmen |
| 5718919 |
Nanoparticles containing the R(-)enantiomer of ibuprofen |
February 17, 1998 |
| There is described a composition comprised of nanoparticles of a therapeutic agent having a surface modifier adsorbed on the surface thereof. The present composition is characterized in that the therapeutic agent is ibuprofen or fenoprofen which is substantially enriched in the R(-) |
| 5716642 |
Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derive |
February 10, 1998 |
| This invention describes the preparation of nanoparticulate pharmaceutical agent dispersion via a process that comprises the dissolution of the said pharmaceutical agent in an alkaline solution and then neutralizing the said solution with an acid in the presence of suitable surface-modif |
| 5705194 |
Pharmaceutical compositions containing polyalkylene block copolymers which gel at physiological |
January 6, 1998 |
| There is disclosed a pharmaceutical composition which gels at physiological temperature. The composition is comprised of a block copolymer containing one or more polyoxyethylene blocks and one or more polyoxy (higher alkylene) blocks wherein at least some of the blocks are linked togethe |
| 5668196 |
3-amido-triiodophenyl esters as x-ray contrast agents |
September 16, 1997 |
| This invention relates to methods of x-ray diagnostic imaging the blood pool, liver, spleen and/or lymph system of a mammal comprising administering a contrast effective amount of a contrast agent having the structure: ##STR1## wherein: n is 0 to 12m is 1 or 2 ##STR2## R. |
| 5665331 |
Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
September 9, 1997 |
| This invention describes the coprecipitation of nanoparticulate pharmaceutical agent dispersion via a process that comprises the dissolution of the said pharmaceutical agent in combination with a crystal growth modifier (CGM) in an alkaline solution and then neutralizing the said sol |
| 5665330 |
Dual purposed diagnostic/therapeutic agent having a tri-iodinated benzoyl group linked to a coum |
September 9, 1997 |
| The invention provides a novel compound having the structure ##STR1## wherein R is alkyl and R1, R2, R3 and R4 are each independently OCH3, H or I and n is 0 or 1 and m is 0 or 1.The compound is useful in a method of treating mammals either therapeutically or imaging mammals for diag |
| 5662883 |
Microprecipitation of micro-nanoparticulate pharmaceutical agents |
September 2, 1997 |
| It has been known that administration of pharmaceutical agents (both diagnostic and therapeutic) with poor water solubility in the form of particles less than 400 nm in diameter produces agent formulation with increased bioavailibility. Bioavailability being proportional to the surfa |
| 5643552 |
Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and |
July 1, 1997 |
| This invention relates to methods of x-ray diagnostic imaging the blood pool, liver, spleen, and/or lymph system of a mammal comprising administering a contrast effective amount of a mixed carbonic anhydride as a contrast agent having the structure ##STR1## X is H, NR.sup.1 R.sup |
| 5628981 |
Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal |
May 13, 1997 |
| Nanoparticulate crystalline x-ray contrast agents are formulated with stabilizers to enhance contact between the crystalline x-ray contrast agents and the gastrointestinal tract.Nanoparticulate crystalline therapeutic substances also formulated with stabilizers to enhance contact between |
| 5622938 |
Sugar base surfactant for nanocrystals |
April 22, 1997 |
| Dispersible particles consisting essentially of a crystalline drug substance having a surface modifier having the formula: ##STR1## wherein R is phenyl-(CH.sub.2).sub.10 CO or C.sub.12 H.sub.25 NHCO adsorbed on the surface thereof in an amount sufficient to maintain an effective |
| 5603916 |
3 5-bis alkanoyl amino-2 4 6-triiodobenzyl esters |
February 18, 1997 |
| This invention relates to methods of x-ray diagnostic imaging the blood pool, liver, spleen and/or lymph system of a mammal comprising administering a contrast effective amount of a contrast agent having the structure: ##STR1## wherein: n is 2;R.sup.1 is H or alkyl containing fro |
| 5593657 |
Barium salt formulations stabilized by non-ionic and anionic stabilizers |
January 14, 1997 |
| Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising nanoparticles of a barium salt having associated with its surface non-ionic and anionic stabilizers; and methods for their use in diagnostic radiology of the gastroin |
| 5591456 |
Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
January 7, 1997 |
| Dispersible particles consisting essentially of crystalline NSAID having hydroxypropyl cellulose adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 1000 nm. Pharmaceutical compositions containing the particles exh |
| 5587143 |
Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticl |
December 24, 1996 |
| This invention provides a composition comprised of nanoparticles containing a therapeutic or diagnostic agent having a nonionic polymeric surfactant as a surface modifier adsorbed on the surface thereof, the surfactant being a block copolymer of ethylene oxide and butylene oxide and a me |
| 5585108 |
Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically ac |
December 17, 1996 |
| Nanoparticulate crystalline therapeutic substances formulated with stabilizers and pharmaceutically acceptable clays to enhance contact between the crystalline therapeutic substances and the gastrointestinal tract and to provide extended therapeutic effect. |
| 5580579 |
Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weig |
December 3, 1996 |
| Nanoparticulate crystalline therapeutic or diagnostic substances formulated with stabilizers and high molecular weight, linear poly(ethylene oxide) polymers, enhance contact between the crystalline therapeutic or diagnostic substances and the gastrointestinal tract providing site-spe |
| 5573783 |
Redispersible nanoparticulate film matrices with protective overcoats |
November 12, 1996 |
| A pharmaceutical film matrix comprising nanoparticles of a low solubility drug associated with a steric stabilizer and a film dispersing agent is coated on the surface of carrier particles and overcoated with a protective layer. Pharmaceutical compositions comprising the film matrix- |
| 5573750 |
Diagnostic imaging x-ray contrast agents |
November 12, 1996 |
| This invention relates to methods of x-ray diagnostic imaging the blood pool, liver, spleen and/or lymph system of a mammal comprising administering a contrast effective amount of a contrast agent having the structure: ##STR1## wherein: X is O, S or NR.sup.4 ;R.sup.3 is alkyl con |
| 5573749 |
Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool a |
November 12, 1996 |
| This invention relates to methods of x-ray diagnostic imaging the blood pool, liver, spleen, and/or lymph system of a mammal comprising administering a contrast effective amount of a mixed carbonic anhydride as a contrast agent having the structure ##STR1## X is H, NR.sup.1 R.sup |
| 5571536 |
Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
November 5, 1996 |
| Nanoparticulate crystalline drug substances formulated in an aqueos phase emulsified in oil, are able to be made at less than 1000 nm size and provide increased bioavailability and lymphatic uptake following oral administration. |
| 5569448 |
Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositio |
October 29, 1996 |
| This invention provides a composition comprised of nanoparticles containing a therapeutic or diagnostic agent having a block copolymer linked to at least one anionic group as a surface modifier adsorbed on the surface thereof and a method of making such nanoparticles. The compositions |
| 5565188 |
Polyalkylene block copolymers as surface modifiers for nanoparticles |
October 15, 1996 |
| There is disclosed a composition containing nanoparticles having a surface modifier wherein the surface modifier is a block copolymer containing one or more polyoxyethylene blocks and one or more polyoxy(higher alkylene) blocks wherein at least some of the blocks are linked together by a |
| 5560932 |
Microprecipitation of nanoparticulate pharmaceutical agents |
October 1, 1996 |
| This invention describes the preparation of nanoparticulate pharmaceutical agent dispersion via a process that comprises the dissolution of the said pharmaceutical agent in an alkaline solution and then neutralizing the said solution with an acid in the presence of a suitable surface |
| 5552160 |
Surface modified NSAID nanoparticles |
September 3, 1996 |
| Dispersible particles consisting essentially of a crystalline NSAID having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 400 nm. Pharmaceutical compositions containing the particles exhibit red |
| 5543133 |
Process of preparing x-ray contrast compositions containing nanoparticles |
August 6, 1996 |
| A process of preparing nanoparticulate contrast agents comprising the steps of:preparing a premix of the contrast agent and a surface modifier; andsubjecting the premix to mechanical means to reduce the particle size of the contrast agent, the mechanical means producing shear, impact, ca |
| 5534270 |
Method of preparing stable drug nanoparticles |
July 9, 1996 |
| Stable dispersible particles consisting essentially of a crystalline drug substance having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 400 nm are prepared by providing a drug substance, d |
| 5525328 |
Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic s |
June 11, 1996 |
| This invention relates to methods of x-ray diagnostic imaging the blood pool and/or lymph system of a mammal comprising administering a contrast effective amount of a particulate iodinated aroyloxy ester contrast agent having the structure: ##STR1## wherein n is an integer from 3 |
| 5521218 |
Nanoparticulate iodipamide derivatives for use as x-ray contrast agents |
May 28, 1996 |
| This invention relates to methods of x-ray diagnostic imaging the blood pool, liver, spleen and/or lymph system of a mammal comprising administering a contrast effective amount of a contrast agent having the structure: ##STR1## wherein: R is alkyl having from 1 to 20 carbon atoms |
| 5518187 |
Method of grinding pharmaceutical substances |
May 21, 1996 |
| A method of preparing particles of a drug substance or diagnostic imaging agent which comprises grinding the drug substance or imaging agent in the presence of grinding media comprising a polymeric resin. The method provides particles exhibiting reduced contamination. |
| 5510118 |
Process for preparing therapeutic compositions containing nanoparticles |
April 23, 1996 |
| A process of preparing nanoparticulate drug substances comprising the steps of: preparing a premix of the drug substance and a surface modifier, and subjecting the premix to mechanical means to reduce the particle size of the drug substance, the mechanical means producing shear, impact, |
